CVI Holdings’s Opus Genetics IRD Stock Holding History

CVI Holdings’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-32,247	Closed	-$1.44M	–	62
2018 Q4	$1.44M	Buy	+32,247	New	+$1.88M	3.21%	7

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

FIM

Frontier Investment Management Dallas, Texas $1.62B AUM 1.86% 1-Year Est. Return

CVI Holdings's IRD Position: Q1 2019 in Review

CVI Holdings sold out of Opus Genetics (IRD) in Q1 2019, closing a stake of 32,247 shares — an estimated $1.44M sold.

CVI Holdings first reported a position in IRD in Q4 2018 and held it in 1 quarter. The position peaked at $1.44M in Q4 2018. 28 funds tracked by Wall St. Rank hold IRD as of Q1 2019.

CVI Holdings reported no remaining Opus Genetics position as of Q1 2019 after selling out during the quarter.
CVI Holdings sold 32,247 Opus Genetics shares in Q1 2019, an estimated $1.44M.
CVI Holdings first reported a position in Opus Genetics in Q4 2018 and held it in 1 quarter.
CVI Holdings's Opus Genetics position peaked at $1.44M in Q4 2018.
28 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2019.

Based on CVI Holdings's 13F filing for Q1 2019, filed 15 May 2019.